within Pharmacolibrary.Drugs.ATC.A;

model A08AA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 2.5e-05,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.001,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A08AA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Mazindol is a tricyclic anorexigenic agent that acts as a sympathomimetic amine. It was formerly used as an appetite suppressant in the management of obesity. Mazindol inhibits the reuptake of norepinephrine and dopamine in the central nervous system. It is not widely approved or used today due to concerns over its safety and side effects.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated as no published, peer-reviewed pharmacokinetic modeling study with complete PK parameters (clearance, volume of distribution, absorption rate) was found in the literature for healthy adults; only basic data on half-life, Tmax, Cmax are reported in some old sources.</p><h4>References</h4><ol><li><p>de Oliveira, MH, et al., &amp; Fröehlich, PE (2016). Pharmacokinetics study of mazindol in plasma, oral fluid, and urine of volunteers. <i>European journal of clinical pharmacology</i> 72(8) 945–951. DOI:<a href=\"https://doi.org/10.1007/s00228-016-2055-8\">10.1007/s00228-016-2055-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27066959/\">https://pubmed.ncbi.nlm.nih.gov/27066959</a></p></li><li><p>Wigal, TL, et al., &amp; Konofal, E (2018). A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). <i>CNS drugs</i> 32(3) 289–301. DOI:<a href=\"https://doi.org/10.1007/s40263-018-0503-y\">10.1007/s40263-018-0503-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29557078/\">https://pubmed.ncbi.nlm.nih.gov/29557078</a></p></li><li><p>Kim, SS, et al., &amp; Lee, KT (2009). Validated method for determination of mazindol in human plasma by liquid chromatography/tandem mass spectrometry. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 877(10) 1011–1016. DOI:<a href=\"https://doi.org/10.1016/j.jchromb.2009.02.049\">10.1016/j.jchromb.2009.02.049</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19272843/\">https://pubmed.ncbi.nlm.nih.gov/19272843</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A08AA05;
